58 OBESITÀ: DA AMPLIFICATORE DI RISCHIO A MALATTIA CRONICA the development of endothelial dysfunction and arterial stiffness. Front Endocrinol. 2013;4:161 51. Liao D, Arnett DK, Tyroler HA, et al. Arterial stiffness and the development of hypertension. The ARIC study. Hypertension. 1999;34:201-6. 52. Li R, Zhang H, Wang W, et al. Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling. Eur J Pharmacol. 2010;628:140-7. 53. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008;51:8-14. 54. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-1904. 55. Korda M, Kubant R, Patton S, et al. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol. 2008;295:H1514-H1521. 56. oillot A, Zoungas S, Mitchell P, et al. for the META-EYE Study Group. Obesity and the microvasculature: a systematic review nd meta-analysis. PlosOne. 2013;8:e52708. 57. Mathiassen ON, Buus NH, Sihm I, et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens. 2007;25:1021-6. 58. Wong TY, Shankar A, Klein R, et al. Prospective cohort study of retinal vessel diameters and risk of hypertension. BMJ. 2004;329:79. 59. Schiffrin EL. Remodelling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens. 2004;17:1192-1200. 60. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78:539-52. 61. Schnabel R, Larson MG, Dupuis J, et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension. 2008;51:1651-7. 62. Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: The Framingham Heart Study. Circulation. 2007;116:1234-41. 63. Faber DR, van der Graaf Y, Westerink J, et al. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases. Atherosclerosis. 2010;212:274-80. 64. Cancello R, Tordjman, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes. 2006;55:1554-61. 65. Roch VZ, Folco EJ. Inflammatory concepts of obesity. Int J Inflam. 2011;2011:529061. 66. Kalupahana NS, Moustaid-moussa N, Claycombe KJ. Immunity s link between obesity and insulin resistance. Mol Aspects Med. 2012;33:26-34. 67. Ohshima K, Mogi M, Jing F, et al. Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance. Hypertension. 2012;59:493-9. 68. Neter JE, Stam BE, Kok FJ et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878-884. 69. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-52. 70. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843-54.
RkJQdWJsaXNoZXIy NDUyNTU=